DNA Collar Strategy
DNA (Ginkgo Bioworks Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
DNA (Ginkgo Bioworks Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $443.6M, a beta of 1.79 versus the broader market, a 52-week range of 5.37-17.58, average daily share volume of 1.2M, a public-listing history dating back to 2021, approximately 485 full-time employees. These structural characteristics shape how DNA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.79 indicates DNA has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a collar on DNA?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
DNA snapshot
As of August 14, 2026, spot at $6.84, ATM IV 78.70%, IV rank 1.01%, expected move 22.56%. The collar on DNA below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this collar structure on DNA specifically: IV regime affects collar pricing on both sides; compressed DNA IV at 78.70% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 22.56% (roughly $1.54 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DNA expiries trade a higher absolute premium for lower per-day decay. Position sizing on DNA should anchor to the underlying notional of $6.84 per share and to the trader's directional view on DNA stock.
DNA collar setup
The DNA collar below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DNA at $6.84 on that close, the first option leg uses a $7.18 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DNA chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DNA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $6.84 | long |
| Sell 1 | Call | $7.18 | N/A |
| Buy 1 | Put | $6.50 | N/A |
DNA collar risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
DNA collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on DNA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use collar on DNA
Collars on DNA hedge an existing long DNA stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
DNA thesis for this collar
The market-implied 1-standard-deviation range for DNA extends from approximately $5.30 on the downside to $8.38 on the upside. A DNA collar hedges an existing long DNA position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current DNA IV rank near 1.01% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DNA at 78.70%. As a Healthcare name, DNA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DNA-specific events.
DNA collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DNA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DNA alongside the broader basket even when DNA-specific fundamentals are unchanged. Always rebuild the position from current DNA chain quotes before placing a trade.
Frequently asked questions
- What is a collar on DNA?
- A collar on DNA is the collar strategy applied to DNA (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With DNA stock at $6.84 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed DNA chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are DNA collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the DNA collar priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 78.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DNA collar?
- The breakeven for the DNA collar priced on this page is no defined breakeven on the modeled curve at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The DNA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 22.56%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on DNA?
- Collars on DNA hedge an existing long DNA stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current DNA implied volatility affect this collar?
- DNA ATM IV is at 78.70% with IV rank near 1.01%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.